Cao Shiliang, Jiang Liang, Yang Shaomin, Liu Zhongjun, Wei Feng, Liu Xiaoguang
Department of Orthopaedics, Peking University Third Hospital, Beijing, China.
Engineering Research Center of Bone and Joint Precision Medicine, Peking University, Bejing, China.
Front Oncol. 2023 Jan 17;12:1063109. doi: 10.3389/fonc.2022.1063109. eCollection 2022.
Spinal tenosynovial giant cell tumor (TGCT) is a rare benign primary spinal tumor with aggressive behavior. The treatment strategy and prognosis of spinal TGCT remain unclear. This retrospective study aimed to evaluate the effectiveness of surgical treatment of spinal TGCT.
We enrolled 18 patients with spinal TGCT who underwent surgical treatment in our hospital between January 2002 and January 2021. Additionally, we reviewed 72 cases of spinal TGCT with surgical treatment reported in the previous literature. Therefore, a total of 90 cases of spinal TGCT were evaluated for their clinical characteristics, surgical details, radiotherapy, and prognosis.
In terms of the extent of resection, 73 cases (81.1%) underwent gross total resection (GTR), and 17 cases (18.9%) underwent subtotal resection (STR). Regarding the technique of GTR, 12 cases (16.7%) underwent en bloc resection, while 60 cases (83.3%) underwent piecemeal resection. During a median follow-up duration of 36 months (range: 3-528 months), 17.8% (16/90) cases experienced local recurrence/progression. The local recurrence/progression rate in cases that underwent GTR was 8.2% (6/73), which was significantly lower than that in cases with STR (58.8%, 10/17) (<0.001). The local recurrence/progression rate of en bloc resection was 8.3% (1/12), and that of piecemeal resection was 8.3% (5/60). Twelve cases underwent perioperative adjuvant radiotherapy, and one (8.3%, 1/12) of them showed disease progression during follow-up. Six recurrent/progressive lesions were given radiotherapy and all of them remained stable in the subsequent follow-up. Eight recurrent/progressive lesions were only treated with re-operation without radiotherapy, and half of them (50.0%, 4/8) demonstrated repeated recurrence/progression in the subsequent follow-up.
Surgical treatment could be effective for spinal TGCT cases, and GTR is the preferred surgical strategy. Piecemeal resection may be appropriate for spinal TGCT cases with an acceptable local recurrence/progression rate. Perioperative adjuvant radiotherapy may reduce the risk of postoperative local recurrence/progression, and radiotherapy plays an important role in the treatment of recurrent/unresectable spinal TGCT lesions.
脊柱腱鞘巨细胞瘤(TGCT)是一种罕见的具有侵袭性的原发性脊柱良性肿瘤。脊柱TGCT的治疗策略和预后仍不明确。本回顾性研究旨在评估脊柱TGCT手术治疗的有效性。
我们纳入了2002年1月至2021年1月期间在我院接受手术治疗的18例脊柱TGCT患者。此外,我们回顾了先前文献报道的72例接受手术治疗的脊柱TGCT病例。因此,共评估了90例脊柱TGCT患者的临床特征、手术细节、放疗及预后情况。
在切除范围方面,73例(81.1%)患者接受了全切除(GTR),17例(18.9%)患者接受了次全切除(STR)。关于GTR技术,12例(16.7%)患者接受了整块切除,而60例(83.3%)患者接受了分块切除。在中位随访期36个月(范围:3 - 528个月)内,17.8%(16/90)的病例出现局部复发/进展。接受GTR的病例局部复发/进展率为8.2%(6/73),显著低于接受STR的病例(58.8%,10/17)(<0.001)。整块切除的局部复发/进展率为8.3%(1/12),分块切除的为8.3%(5/60)。12例患者接受了围手术期辅助放疗,其中1例(8.3%,1/12)在随访期间出现疾病进展。6例复发/进展性病变接受了放疗,且在随后的随访中均保持稳定。8例复发/进展性病变仅接受了再次手术而未进行放疗,其中一半(50.0%,4/8)在随后的随访中出现反复复发/进展。
手术治疗对脊柱TGCT病例可能有效,GTR是首选的手术策略。对于局部复发/进展率可接受的脊柱TGCT病例,分块切除可能是合适的。围手术期辅助放疗可能降低术后局部复发/进展的风险,放疗在复发性/不可切除性脊柱TGCT病变的治疗中起重要作用。